Abstract

Background/aimsChildren with idiopathic short stature (ISS) constitute a heterogenous group. Recombinant IGF-I (rhIGF-I) have been licensed for the treatment of severe short stature (height <−3 standard deviation scores (SDS)) in...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call